{"authors":[{"id":"6f6a18d4-69d0-4df5-860d-a580932584db","index":0,"name":"Jonathan Fior","nodesUserId":-1,"orcid":"0000-0002-5283-407X","role":"Author","type":"contributor"},{"id":"c06de1df-f578-4977-b6df-fac02ac97dd9","name":"jonathan.fior82@gmail.com","role":"Author","nodesUserId":-1}],"components":[{"id":"root","name":"root","payload":{"cid":"bafybeif6tr2yhn5kvsmhhmnt6rumhuctob57ar77jk4dgutorztl6weote","path":"root"},"type":{".pdf":"pdf",".xls":"data"}},{"id":"48230fe8-a071-421a-bb8d-f0930f61d656","name":"vaccines-04-00013-v2.pdf","payload":{"cid":"bafybeifsoqaim2uscey43z3g22wdfh3uv5eyhxngbjm2bkfq4yo2q4vhdq","description":"ior, J. SupT1 Cell Infusion as a Possible Cell-Based Therapy for HIV: Results from a Pilot Study in Hu-PBMC BRGS Mice. Vaccines 2016, 4, 13. https://doi.org/10.3390/vaccines4020013","licenseType":"cc by","path":"root/vaccines-04-00013-v2.pdf","title":"SupT1 Cell Infusion as a Possible Cell-Based Therapy for HIV: Results from a Pilot Study in Hu-PBMC BRGS Mice"},"starred":false,"type":"pdf"}],"defaultLicense":"CC BY","description":"In a previous in vitro study, the SupT1 cell line was explored as a decoy target for HIV-1, proposing SupT1 cell infusion as a possible cell-based therapy for HIV. In the present work, the previous in vitro model was translated into an in vivo setting. Specifically, Hu-PBMC BRGS mice were infected with a high input of HIV-1 LAI (100,000 TCID50), and 40 million 30 Gy-irradiated SupT1 cells were infused weekly for 4 weeks as a therapy. Blood samples were taken to monitor CD4+ T cell count and viral load, and mice were monitored daily for signs of illness. At the earliest time point analyzed (Week 1), there was a significantly lower plasma viral load (~10-fold) in all animals treated with SupT1 cell infusion, associated with a higher CD4+ T cell count. At later time points, infection proceeded with robust viral replication and evident CD4+ T cell depletion, except in one mouse that showed complete suppression of viral replication and preservation of CD4+ T cell count. No morbidity or mortality was associated with SupT1 cell infusion. The interesting tendencies observed in the generated data suggest that this approach should be further investigated as a possible cell-based HIV therapy.","dpid":{"id":"239","prefix":"beta"},"researchFields":[],"title":"SupT1 Cell Infusion as an HIV cure ","version":"desci-nodes-0.2.0"}